Product Design, Manufacturing & Innovation Resources

Neueste Veröffentlichungen und Patente im Bereich der molekularen Onkologie

Publikationen und Patente im Bereich der molekularen Onkologie

Tipp: Zusätzlich zu der unten stehenden Auswahl können Sie unsere 2 gesamten Datenbanken durchsuchen und filtern:

> Kostenloses Tool zur Suche nach Veröffentlichungen < nach Autor, Thema, Stichwörtern, Datum oder Zeitschrift.

> Kostenloses Tool zur Suche nach Patenten < für Patente in englischer Sprache vom Europäischen Patentamt.

Molekulare Onkologie
Molecular oncology leverages advanced Technologien to innovate cancer diagnosis and treatment through genetic and biochemical insights.

Die molekulare Onkologie erforscht die genetischen, epigenetischen und biochemischen Veränderungen, die die Entstehung, das Fortschreiten und die Therapieresistenz von Krebs bedingen. Dieses Forschungsgebiet integriert Hochdurchsatzsequenzierung, molekulare Diagnostik und zielgerichtete Therapien, um onkogene Signalwege, die Inaktivierung von Tumorsuppressorgenen und Wechselwirkungen mit der Tumormikroumgebung aufzuklären. Fortschritte in der molekularen Profilierung, der Biomarker-Entdeckung und der Präzisionsmedizin verändern die Krebsklassifizierung und Behandlungsstrategien grundlegend. Die folgende Zusammenstellung präsentiert die neuesten peer-reviewten Publikationen und patentierten Innovationen und spiegelt die Spitzenforschung zu Onkogenen, Signaltransduktion, Krebsstammzellen, Immunmodulation und molekularen Bildgebungsverfahren wider, die für die translationale Onkologie und klinische Anwendungen unerlässlich sind.

Dies ist unsere neueste Auswahl an weltweiten Veröffentlichungen und Patenten in englischer Sprache zum Thema Molekulare Onkologie, die in vielen wissenschaftlichen Online-Zeitschriften zu den Themen Onkogene, Tumorsuppression, Signaltransduktionswege, Krebsgenomik, Epigenetik bei Krebs, molekulare Biomarker, gezielte Krebstherapie, Krebszellsignalisierung, DNA-Mutation, microRNAs in der Onkologie, Krebsstammzellen, Apoptoseregulation klassifiziert sind, Tumormikroumgebung, Krebsimmuntherapie, Genexpressionsprofile, Chromosomenaberrationen, molekulare Diagnostik, Krebsproteomik, onkogene Stoffwechselwege, Krebsmetastasen, molekulare Mechanismen der Krebsentstehung, Tumorheterogenität, Krebsepigenomik, onkogene Viren, molekulare zielgerichtete Arzneimittel, Krebstranskriptomik, DNA-Reparaturmechanismen, pharmakogenomische Krebsforschung und molekulare Krebspathologie.

A perspective on gene expression and regional brain sensitivity

Published on 2026-07-08 by @MIT

Abstract: AbstractNon-invasive transcranial ultrasound stimulation (TUS) enables deep brain therapeutic exploration at unprecedented scale. However, its optimal use is limited by the uncertainty surrounding ultrasound sensitivity across brain regions and cell types. This uncertainty often forces selection of sub-optimal parameter–target treatment paradigms guided solely by precedent, rather than an unbiased search of the larger combinatorial space. In principle, human brain-wide gene expression data cou[...]


Our summary: This perspective discusses the use of gene expression data to enhance transcranial ultrasound stimulation (TUS) parameter selection. It highlights the identification of regional gene expression clusters that may respond similarly to TUS. The findings emphasize the importance of optimizing stimulation parameters based on molecular profiles across different brain regions.

gene expression, transcranial ultrasound stimulation, brain regions, neuromodulation

Publication

Heterobifunctional compounds for the degradation of kras protein

Patent published on the 2026-07-02 in WO under Ref WO2026139448 by MERCK PATENT GMBH [DE] (Anderson Corey Don [us], Cheng Xinpeng [us])

Abstract: The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.[...]


Our summary: The invention focuses on heterobifunctional compounds that target and degrade the KRAS protein, including its mutant forms. These compounds facilitate ubiquitination of KRAS, leading to its proteasomal degradation. They hold potential for treating various types of cancer.

Heterobifunctional compounds, KRAS protein, ubiquitination, proteasomal degradation

Patent

Chimeric antigen receptor fc-engineered granulocyte-monocyte progenitors for enhanced cancer immunotherapy

Patent published on the 2026-06-25 in WO under Ref WO2026136621 by UNIV SOUTHERN CALIFORNIA [US] (Majeti Ravindra [us], Ying Qi-long [us], Yue Shi [us])

Abstract: Provided herein are chimeric antigen receptors, comprising an extracellular domain capable of binding to an antigen, an Fc region, a flexible linker, a transmembrane domain, and may further comprise at least one intracellular domain that is designed to increase the anti-tumor activities of granulocytes, macrophages, and dendritic cells by increasing their phagocytosis and/or proinflammatory cytokines secretion and/or antigen presentation. Provided herein are vectors and nucleic acid molecules en[...]


Our summary: This content discusses the development of chimeric antigen receptors with Fc-engineering to enhance the anti-tumor activities of granulocyte-monocyte progenitors. It details methods for genetically engineering these progenitors to express the receptors and their potential differentiation into macrophages or granulocytes. The ultimate goal is to utilize these engineered cells in immunotherapy for cancer treatment.

chimeric antigen receptor, granulocyte-monocyte progenitors, cancer immunotherapy, Fc-engineering

Patent

Multifunctional molecules comprising soluble tcr fragments and uses thereof

Patent published on the 2026-06-18 in WO under Ref WO2026125496 by ENGIMMUNE THERAPEUTICS AG [CH] (Wehrle Sarah [ch], Lalevee SÉbastien [ch], Yang Qinmei [ch], Vazquez-lombardi Rodrigo [ch], Ehling Roy [ch], Crook Kenneth [ch], Kucharczyk Jakub [ch])

Abstract: The present invention is in the field of immunotherapy, in particular cancer immunotherapy and relates to multifunctional molecules comprising at least a soluble TCR fragment, a CD3 agonist, a CD2 agonist and optionally, an antibody Fc region. Furthermore, the invention relates to methods of making the multifunctional molecule according to the invention, as well as therapeutic uses thereof.[...]


Our summary: The invention describes multifunctional molecules that include soluble TCR fragments and CD3/CD2 agonists. These molecules are designed for applications in cancer immunotherapy. Methods for their production and therapeutic uses are also outlined.

multifunctional molecules, soluble TCR fragments, cancer immunotherapy, CD3 agonist

Patent

Lineage-loci engineered cell therapy and related methods of producing and using same

Patent published on the 2026-06-11 in WO under Ref WO2026123001 by UMOJA BIOPHARMA INC [US] (O'hara Samantha [us], Romanov Artem [us], Koning Ryan [us], Vereide David T [us], Yingst Ashley M [us], Jarrell Dillon [us])

Abstract: Provided herein are genetically engineered cells containing a payload in a lineage specific locus and related methods and uses thereof in cell therapy. In some embodiments, the cells are genetically engineered with a CAR, such that expression of the CAR is delayed until the cell is differentiated to a lineage. In some embodiments, the genetically modified cells can be selected for using a selection cassette. Also provided are cell compositions containing the engineered cells, and related methods[...]


Our summary: This content discusses lineage-loci engineered cell therapy and methods for producing genetically engineered cells. It highlights the use of CARs that are expressed upon cell differentiation. Additionally, it covers cell compositions, selection methods, and applications in cancer immunotherapy.

cell therapy, genetically engineered cells, CAR, lineage-specific locus

Patent

Tumor antigens for ovarian cancer and uses thereof

Patent published on the 2026-05-28 in WO under Ref WO2026107594 by UNIV DE MONTREAL [CA] (Perreault Claude [ca], Thibault Pierre [ca], Hardy Marie-pierre [ca], Vincent Krystel [ca])

Abstract: Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor [...]


Our summary: Novel tumor antigens for high-grade serous ovarian cancer are identified, derived from aberrantly expressed genomic sequences. These antigens are not present in normal tissues and may elicit immune responses. The study discusses their potential use in treatments, including nucleic acids, compositions, cells, and vaccines.

tumor antigens, ovarian cancer, immunotherapy, vaccines

Patent

A fluid processing device for processing droplets

Patent published on the 2026-05-06 in EP under Ref EP4737004 by IMEC VZW [BE] (Yurt Abdulkadir [be], Set Ying Ting [be], Moloudi Reza [be], Vandevelde Bart [be])

Abstract: [0001] The present invention relates to a fluid processing device for processing droplets. The device comprises a plate-like structure comprising a plurality of functional pixels. Each functional pixel is adapted to perform multiple operations on a droplet located on the pixel. Specifically, each pixel can selectively carry out at least two of the following processing operations: manipulating the droplet (e.g., its position), applying heat to the droplet, and subjecting the droplet to a magnetic[...]


Our summary: The invention is a fluid processing device designed for droplet manipulation. It features a plate-like structure with functional pixels that can perform multiple operations on droplets. This device integrates various microfluidic functions into a compact platform for applications in biochemical analysis and drug discovery.

microfluidics, droplet manipulation, functional pixels, biochemical analysis

Patent

Glioblastoma-Derived Extracellular Vesicles Modulate &gamma;&delta; T Lymphocytes Through a MIC-Dependent Mechanism

Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI

Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. &amp;gamma;&amp;delta; T lymphocytes are immune cells that can migrate to tumors and induce malignant cells&amp;rsquo; apoptosis. Our previous in silico studies showed that higher &amp;gamma;&amp;delta; T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]


Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.

Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy

Publication

Behandelte Themen: Molekulare Onkologie, genetische Veränderungen, epigenetische Veränderungen, biochemische Veränderungen, Hochdurchsatzsequenzierung, molekulare Diagnostik, zielgerichtete Therapeutika, onkogene Signalwege, Tumorsuppressorgene, Tumormikroumgebung, Entdeckung von Biomarkern, Präzisionsmedizin, Krebsklassifizierung, Immunmodulation, molekulare Bildgebung, translationale Onkologie, klinische Anwendungen, von Experten begutachtete Veröffentlichungen, patentierte Innovationen ISO 15189, ISO 9001, ISO/IEC 17025, CLSI-Richtlinien und ASTM E2876.

Historischer Kontext

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(wenn das Datum unbekannt oder nicht relevant ist, z. B. „Strömungsmechanik“, wird eine gerundete Schätzung seines bemerkenswerten Auftretens bereitgestellt)

Bilder in voller Größe und Downloads sind nur für registrierte Mitglieder 100% kostenlos verfügbar.

> Login <